Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Pegylated Liposomal Doxorubicin (Caelyx(R)) as Monotherapy in Elderly Patients With Locally Advanced and/or Metastatic Breast Cancer (Study P05059)

This study has been terminated.
Sponsor:
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier:
NCT00604968
First received: January 21, 2008
Last updated: October 1, 2014
Last verified: October 2014

January 21, 2008
October 1, 2014
February 2007
October 2009   (final data collection date for primary outcome measure)
Time to Treatment Failure (Defined as Progression of Disease [According to the Response Evaluation Criteria in Solid Tumors (RECIST) or World Health Organization (WHO) Criteria] or Unacceptable Toxicity Leading to Discontinuation of Treatment or Death). [ Time Frame: Time of treatment until progression of disease or unacceptable toxicity leading to discontinuation of treatment or death, assessed every 12th week until end of treatment (study planned to continue until all participants ended treatment). ] [ Designated as safety issue: No ]
Treatment failure was defined as progression of disease (according to the RECIST or WHO criteria) or unacceptable toxicity leading to discontinuation of treatment or death. Progressive Disease according to RECIST response criteria: >=20% increase in the sum of the Longest Diameter of target lesions or unequivocal progression of non-target lesions. Appearance of new lesions will also constitute progressive disease. Progressive Disease according to WHO response criteria: Increase in size of existing lesions or appearance of new lesions.
Time to treatment failure. Treatment failure is defined as progression of disease (according to the RECIST or WHO criteria) or unacceptable toxicity leading to discontinuation of treatment or death. [ Time Frame: Until progression of disease (according to the RECIST or WHO criteria) or unacceptable toxicity leading to discontinuation of treatment or death ] [ Designated as safety issue: Yes ]
Complete list of historical versions of study NCT00604968 on ClinicalTrials.gov Archive Site
  • Number of Patients With Stable Disease (SD) as Best Response [ Time Frame: Time of treatment until treatment discontinuation, assessed every 12th week until end of treatment (study planned to continue until all participants ended treatment). ] [ Designated as safety issue: No ]

    Response was calculated according to RECIST criteria except for bone metastasis where WHO criteria was used. For patients with skeletal disease only, WHO criteria was used. For patients with measurable disease according to RECIST as well as bone metastasis, both RECIST & WHO were used.

    RECIST response criteria for SD required steady state of response of at least 9 weeks duration. There may be no appearance of new lesions.

    WHO response criteria for SD required no significant change for at least 8 weeks.

  • Number of Patients With Partial Response (PR) as Best Response [ Time Frame: Time of treatment until treatment discontinuation, assessed every 12th week until end of treatment (study planned to continue until all participants ended treatment). ] [ Designated as safety issue: No ]

    Response was calculated according to RECIST criteria except for bone metastasis where WHO criteria was used. For patients with skeletal disease only, WHO criteria was used. For patients with measurable disease according to RECIST as well as bone metastasis, both RECIST & WHO were used.

    RECIST PR criteria required >=30% decrease in certain target lesions & no increase in size of non-target lesions or appearance of new lesions

    WHO PR criteria required partial decrease in size of lytic lesions, recalcification of lytic lesions, or decreased density of blastic lesions for >=4 wks

  • Number of Patients With Progressive Disease (PD) as Best Response [ Time Frame: Time of treatment until treatment discontinuation, assessed every 12th week until end of treatment (study planned to continue until all participants ended treatment). ] [ Designated as safety issue: No ]

    Response was calculated according to RECIST criteria except for bone metastasis where WHO criteria was used. For patients with skeletal disease only, WHO criteria was used. For patients with measurable disease according to RECIST as well as bone metastasis, both RECIST & WHO were used.

    RECIST PD criteria required >=20% increase in certain target lesions OR progression of non-target lesions, or appearance of new lesions

    WHO PD criteria required increase in size of existing lesions or appearance of new lesions.

  • Number of Patients Requiring Dose Reduction [ Time Frame: Time of treatment until treatment discontinuation (study planned to continue until all participants ended treatment). ] [ Designated as safety issue: Yes ]
    The protocol contains instructions to reduce the Caelyx dose according to specific schedules, in cases necessary due to reasons such as hematological toxicity, non-hematological toxicity, cardiotoxicity, or other toxic side-effects of treatment reducing quality of life etc.
  • Time to Response [ Time Frame: Time of treatment until response, assessed every 12th week until end of treatment (study planned to continue until all participants ended treatment). ] [ Designated as safety issue: No ]
    Response can be partial (>=30% decrease in the sum of Longest Diameter of target lesions, determined by two observations not less than 4 weeks apart; no unequivocal increase in the size of non-target lesions or the appearance of new lesions may occur) or complete (disappearance of all clinical evidence of tumor determined by 2 observations not less than 4 weeks apart), whichever status is recorded first.
  • Duration of Response [ Time Frame: Time of treatment until treatment discontinuation, assessed every 12th week until end of treatment (study planned to continue until all participants ended treatment). ] [ Designated as safety issue: No ]

    Duration of response is defined as the time span from the first evaluation that shows response until the first evaluation that shows progression. Where patients did not show progress, duration of response was measured from the first evaluation that showed response until they discontinued the study.

    Response can be partial or complete (as previously defined), whichever status is recorded first.

  • Time to Progression [ Time Frame: Time of treatment until progression, assessed every 12th week until end of treatment (study planned to continue until all participants ended treatment). ] [ Designated as safety issue: No ]

    Progression is defined as the first evaluation that shows progression (either by RECIST or WHO criteria):

    Progressive Disease according to RECIST response criteria: >=20% increase in the sum of the Longest Diameter of target lesions or unequivocal progression of non-target lesions. Appearance of new lesions will also constitute progressive disease.

    Progressive Disease according to WHO response criteria: Increase in size of existing lesions or appearance of new lesions.

  • Duration of Overall Survival [ Time Frame: Time of treatment until death, up to the time that all participants ended treatment ] [ Designated as safety issue: No ]
    Patients were followed with regards to survival even after they left the trial (ie after End of Treatment visit). Deaths that occurred after patient participation ended were collected all the way through to the overall end of the trial which took place on Oct 31, 2009. These deaths were used to calculate overall survival.
  • Number of Days the Patients Were Hospitalized for Cancer-related Symptoms or Toxicity of Treatment [ Time Frame: Time of treatment until treatment discontinuation (study planned to continue until all participants ended treatment). ] [ Designated as safety issue: No ]
    The cumulative sum of hospitalization days during the study, per patient. Some patients had multiple hospitalizations.
Safety, response rate, time to progression, survival, symptom control measured by patient assessment, quality of life, and analysis of treatment predictive factors in tumor tissue and angiogenetic factors, proteomics and snp-analysis in serum/plasma. [ Time Frame: Time to response, duration of response, time to progression and survival will be calculated. The proportion of patients having QoL at 3 months unchanged or better than at the time of inclusion will be calculated. ] [ Designated as safety issue: Yes ]
Not Provided
Not Provided
 
Pegylated Liposomal Doxorubicin (Caelyx(R)) as Monotherapy in Elderly Patients With Locally Advanced and/or Metastatic Breast Cancer (Study P05059)
Caelyx(R) in Breast Cancer in the Elderly. Pegylated Liposomal Doxorubicin (Caelyx(R)) as Monotherapy in Elderly Patients With Locally Advanced and/or Metastatic Breast Cancer.

The purpose of this study is to evaluate the safety and efficacy of pegylated liposomal doxorubicin (Caelyx) in elderly patients who are to receive first-line chemotherapy for metastatic or locally advanced breast cancer, not amenable to surgery.

Not Provided
Interventional
Phase 4
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Breast Neoplasms
Drug: Caelyx (pegylated liposomal doxorubicin; SCH 200746)
Caelyx will be administered intravenously at a dose of 40 mg/m^2 on day one every 4 weeks until progression, or unacceptable toxicity, or other reason to discontinue the study treatment. The drug is diluted in 250 ml glucose 5% (500 ml for doses >=90 mg).
Experimental: Caelyx
Intervention: Drug: Caelyx (pegylated liposomal doxorubicin; SCH 200746)
Green H, Stål O, Bachmeier K, Bäcklund LM, Carlsson L, Hansen J, Lagerlund M, Norberg B, Franzén Å, Åleskog A, Malmström A. Pegylated liposomal doxorubicin as first-line monotherapy in elderly women with locally advanced or metastatic breast cancer: novel treatment predictive factors identified. Cancer Lett. 2011 Dec 27;313(2):145-53. doi: 10.1016/j.canlet.2011.07.017. Epub 2011 Aug 31.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
25
October 2009
October 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients meeting the following criteria will be eligible for enrollment.

    • Female patients with histologic or cytologic diagnosis of breast cancer that is locally advanced or metastatic, and not amenable to surgery.
    • Age >= 65 years.
    • World Health Organization (WHO) Performance Status 0 - 2
    • Measurable disease in accordance with Response Evaluation Criteria in Solid Tumors (RECIST) criteria. Patients with bone metastasis can also be included but will be evaluated according to WHO criteria. Patients with non-measurable disease can also be included.
    • Left ventricular ejection fraction (LVEF) >= 50% verified by ultrasound cardiography (UCG); no clinical signs of heart disease.
    • Normal organ function, except due to disease involvement, however maximum deviation:

      • S-creatinine <= 1.5 x upper normal limit;
      • Bilirubin <= 2 x upper normal limit;
      • Alanine aminotransferase (ALAT) and/or aspartate aminotransferase (ASAT) <= 3 x upper normal limit. In case of liver metastases, ALAT and/or ASAT <= 5 x upper normal limit.
    • Adequate bone marrow function, ie:

      • Platelets >= 100 x 10^9/L;
      • Neutrophils >= 1.5 x 10^9/L;
      • White Blood Cell (WBC) >= 3.0 x 10^9/L;
      • Hemoglobin > 90 g/L.
    • Life expectancy >= 12 weeks.
    • Patients having received oral and written information and having provided written informed consent.

Exclusion Criteria:

  • Patients will not be enrolled if any of the following conditions apply.

    • Previous chemotherapy for metastatic disease. (The patient may have received previous endocrine therapy or single-drug Herceptin. Intrapleural or intrapericardial Novantrone is allowed.)
    • Recurrence <= 12 months after adjuvant anthracycline-containing treatment and/or prior doxorubicin > 300 mg/m^2 or epirubicin > 540 mg/m^2.
    • Myocardial infarction within 6 months of planned inclusion.
    • Symptomatic brain metastases.
    • Human Epidermal growth factor Receptor 2 (HER-2) positivity eligible for treatment with trastuzumab, or estrogen receptor (ER) positivity eligible for hormonal therapy.
    • Allergy to anthracyclines.
    • Uncontrolled infection.
    • Other not radically treated malignancy.
    • Other disease or condition contraindicating treatment or not allowing follow-up.
Female
65 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00604968
P05059
No
Merck Sharp & Dohme Corp.
Merck Sharp & Dohme Corp.
Not Provided
Not Provided
Merck Sharp & Dohme Corp.
October 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP